Cardiome’s BRINAVESS Demonstrates 74% Cardioversion in Post-Cardiac Surgery Patients with Atrial Fibrillation

[PR Newswire] – NASDAQ: CRME TSX: COM VANCOUVER, Feb. 13, 2014 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announced that a poster titled Medical conversion with Vernakalant on postoperative … more

View todays social media effects on CRME

View the latest stocks trending across Twitter. Click to view dashboard

See who Cardiome is hiring next, click here to view